StockCIK 1813814
Definium Therapeutics, Inc. (DFTX): Insider Trades and Fund Holdings
In the past 12 months, Definium Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 6 sales worth $3.02M; 6 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$3.02MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 29, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 29 | Robert BarrowCEO | ▼ SELL10b5-1 | $1.15M |
| Sep 29 | Mark SullivanGeneral Counsel | ▼ SELL10b5-1 | $514K |
| Sep 29 | Daniel KarlinChief Medical Officer | ▼ SELL10b5-1 | $397K |
| Sep 29 | Brandi RobertsCFO | ▼ SELL10b5-1 | $123K |
| Sep 29 | Matthew T. WileyChief Commercial Officer | ▼ SELL10b5-1 | $113K |
| Sep 4 | Robert BarrowCEO | ▼ SELL10b5-1 | $722K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Robert Barrow | CEO | 0 | $0 | 2 | $1.88M |
| Mark Sullivan | General Counsel | 0 | $0 | 1 | $514K |
| Daniel Karlin | Chief Medical Officer | 0 | $0 | 1 | $397K |
| Brandi Roberts | CFO | 0 | $0 | 1 | $123K |
| Matthew T. Wiley | Chief Commercial Officer | 0 | $0 | 1 | $113K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report DFTX
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Duquesne Family Office | 356,600 | $17K | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →